Although navitoclax has shown encouraging activity in hematologic malignancies as a single agent and in the adjuvant setting, its clinical utility is limited by thrombocytopenia driven by inhibition of BCL-XL. This evidence concerns the gene BCL2L1 and Thrombocytopenia.